BioLife Solutions Inc
$ 33.93
0.38%
06 Aug - close price
- Market Cap 1,657,732,000 USD
- Current Price $ 33.93
- High / Low $ 34.34 / 33.60
- Stock P/E N/A
- Book Value 7.72
- EPS -0.24
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA N/A %
- ROE -0.03 %
- 52 Week High 34.34
- 52 Week Low 17.86
About
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the gene and cell therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company is headquartered in Bothell, Washington.
Analyst Target Price
$31.12
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-03 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-02-29 | 2023-11-09 |
| Reported EPS | 0.0843 | 0.04 | 0.04 | 0.04 | -0.33 | 0.04 | -0.016 | -0.02 | -0.05 | -0.23 | -0.21 | -0.34 |
| Estimated EPS | -0.01 | 0.02 | -0.02 | -0.0113 | -0.02 | -0.04 | -0.0567 | -0.05 | -0.09 | -0.28 | -0.27 | -0.28 |
| Surprise | 0.0943 | 0.02 | 0.06 | 0.0513 | -0.31 | 0.08 | 0.0407 | 0.03 | 0.04 | 0.05 | 0.06 | -0.06 |
| Surprise Percentage | 943% | 100% | 300% | 453.9823% | -1550% | 200% | 71.7813% | 60% | 44.4444% | 17.8571% | 22.2222% | -21.4286% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BLFS
2026-08-07 08:41:07
Royal Bank of Canada increased its stake in BioLife Solutions (NASDAQ:BLFS) by 8.1%, purchasing an additional 66,010 shares, bringing its total to 885,298 shares valued at approximately $16.9 million. This transaction comes as other institutional investors have adjusted their positions, and despite a major insider sale, BioLife Solutions reported quarterly earnings per share of $0.04, beating estimates. Analysts maintain a "Hold" rating with a consensus target price of $31.38, while the stock trades at $33.93.
2026-08-07 08:13:07
BioLife Solutions (BLFS) reported a significant turnaround in Q2 2026, swinging from a net loss to a profit of US$45.10 million on US$28.47 million in sales. This positive financial performance comes shortly after the announcement of its US$1.6 billion acquisition by Repligen. The article highlights that while the improved earnings are positive, risks such as customer concentration and execution on new products remain, and the acquisition shifts the focus to deal completion and integration.
2026-08-06 20:41:07
BioLife Solutions (NASDAQ: BLFS) has reported strong Q2 2026 financial results, with revenue reaching $28.5 million and net income from continuing operations at $45.1 million, largely due to a significant income tax benefit. The company also announced a cash-and-stock merger agreement with Repligen, where each BioLife share will be exchanged for $11.25 in cash and 0.1442 Repligen shares, with the merger expected to close in Q4 2026. This move follows BioLife's recent divestiture of its SAVSU business and aims to integrate its bioproduction products and services into Repligen's operations.
2026-08-06 20:34:08
BioLife Solutions, Inc. (BLFS) announced its Q2 revenue of $28.5 million, surpassing the FactSet estimate of $27.8 million. The company's stock, listed on Nasdaq, closed at $33.93 on August 6th, marking a 0.38% increase for the day. This positive earnings report follows a series of recent downgrades from several analysts and an acquisition agreement by Repligen Corporation for approximately $1.6 billion.
2026-08-06 19:40:08
BioLife Solutions announced its Q2 2026 financial results, reporting total revenue of $28.5 million, a 21% increase over Q2 2025, and GAAP net income of $45.1 million, which included a significant non-cash income tax benefit. The company also confirmed its pending acquisition by Repligen for approximately $1.5 billion, expected to close in Q4 2026. This acquisition will result in BioLife ceasing to be a publicly traded company.
2026-08-05 17:20:47
BioLife Solutions Inc. (NASDAQ:BLFS) stock recently hit a 52-week high of $33.18, reflecting a 56.33% increase over the past year and a current market capitalization of $1.61 billion. Despite strong revenue growth and analyst predictions of profitability, InvestingPro analysis suggests the stock may be overvalued. Additionally, Repligen announced plans to acquire BioLife Solutions for $31 per share, leading to a downgrade from TD Cowen.
